Clinical Research Directory
Browse clinical research sites, groups, and studies.
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
Sponsor: Shanghai Changzheng Hospital
Summary
This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.
Official title: A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics and Efficacy of Subcutaneous Injection of MSC303 for the Treatment of Immune Glomerular Diseases
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2025-06-20
Completion Date
2027-02-20
Last Updated
2025-06-11
Healthy Volunteers
No
Interventions
Injection of MSC303
Dose Group 1: D1, D8, D15, and D36 were respectively given 1, 5, 15, and 15 mg of MSC303 for injection; The second dose group: D1, D8, D15 and D36 were respectively given for injection MSC303 1, 5, 20, 20 mg.
Locations (1)
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China